Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- Roundtable Top Picks of the Week
- FED Front & Center Again
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- 3 Japanese Stocks to Buy Now
- Your Next Stock Should Be Making New Highs
- Anatomy of Success: Stoneridge (SRI)
- RTI: What Will the Fed Do Wednesday?
- AWS 6/18: Can the Fed Afford to Keep the Suspense?
- PFP 6/18: Wednesday Fed Watch
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/18/2013
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
MannKind Corporation (MNKD - Analyst Report) reported a loss of 23 cents per share in the second quarter of 2012, narrower than the year-ago loss of 37 cents per share and the Zacks Consensus Estimate of a loss of 25 cents.
Quarter in Detail
MannKind did not generate any revenues in the second quarter of 2012 as well as in the year-ago period.
Research and development (R&D) expenses declined 12.1% to $26.6 million in the reported quarter. Despite an increase in trial-related costs, R&D expenses declined mainly due to the settlement of the insulin supply agreement with N.V. Organon, a subsidiary of Merck & Co. Inc. (MRK - Analyst Report), following the termination of the program in June 2011.
MannKind is primarily focusing on the development of its lead pipeline candidate Afrezza. Afrezza, an inhaled insulin, is being developed for the treatment of type I (MKC-171 study) or type II diabetes (MKC-175 study). The company has completed more than 87% screening for MKC 171 and 83% screening for MKC 175. MannKind screened more patients than it expected in both the trials due to a higher screen failure rate. MannKind expects to finish screening in both the trials by September 2012. The company believes it can complete both trials in the second quarter of 2013 and submit a new drug application by the third quarter of 2013.
General and administrative expenses increased approximately 95.5% in the reported quarter to $17.4 million. The increase was primarily attributable to a litigation settlement amount of $7.7 million during the reported quarter along with higher legal fees and financing transaction cost.
MannKind is looking for more financing agreements to fund its trials. Though the company believes its funds are sufficient to finance operations into the fourth quarter of 2012, we believe the company will look to raise funds again later this year. Inability to raise sufficient funds will jeopardize Afrezza’s future.
Our View
Currently, we have a Neutral recommendation on MannKind, which carries a Zacks #4 Rank (short-term Sell rating). MannKind is primarily dependent on the successful development of Afrezza and we expect investor focus to remain on it.
Get the full Analyst Report on MNKD - FREE
Get the full Analyst Report on MRK - FREE